Laboratory (LH) Received its Third Buy in a Row

After Mizuho Securities and Robert W. Baird gave Laboratory (NYSE: LH) a Buy rating last month, the company received another Buy, this time from Wells Fargo. Analyst Timothy Daley maintained a Buy rating on Laboratory today and set a price target of $315.00. The company’s shares closed last Monday at $261.24, close to its 52-week low of $256.81.

According to, Daley is a 2-star analyst with an average return of 0.3% and a 50.0% success rate. Daley covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, Stevanato Group, and Mettler-Toledo.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Laboratory with a $341.27 average price target, representing a 28.0% upside. In a report issued on April 18, Robert W. Baird also maintained a Buy rating on the stock with a $347.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $317.17 and a one-year low of $256.81. Currently, Laboratory has an average volume of 872.5K.

Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing. The Covance Drug Development segment involves in providing drug development solutions, to companies in the pharmaceutical and biotechnology industries. The company was founded in 1971 and is headquartered in Burlington, NC.

Read More on LH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More